MicroRNA-32 Suppression: its Effects on Prostate Cancer Cells’ Capability to Proliferate and Migrate

Abstract

Introduction This paper sought to scrutinize the role of microRNA-32 (miR-32) on the growth and migration as well as on the expression of metastatic genes in PC3 cells of prostate cancer in vitro. Methods Subsequent transfection of cells with miR-32 mimics, miR-32 inhibitor, negative control (NC), cell proliferation using MTT, and apoptosis by ELISA were performed. Furthermore, qRT-PCR was directed to measure the expression levels of matrix metalloproteinase 2 (MMP2) and vascular endothelial growth factors (VEGF) as metastatic and angiogenesis genes in the progression of PC3. Results miR-32 was overexpressed in PC3 cells compared to normal cells (P<0.001). Down-regulation of miR-32 obstructs in vitro proliferation and migration while intensifying the apoptosis rate in PC3 cells. Also, we found that miR-32 negatively modulates the expression of VEGF and MMP2 in PC3 cells. Conclusion These results indicate that the suppression of miR-32 might offer an auxiliary treatment procedure for addressing the invasion, progression, and metastasis in PCa patients by improving cell apoptosis.

Bioengineered chimeric tRNA/pre‐miRNAs as prodrugs in cancer therapy

“…Animal models of various cancers and clinical studies showed that there is a causal relationship between miRNAs and cancer development, and as a result, miRNAs quickly entered the clinical stage as biomarkers and therapeutic targets. [42][43][44][45] miRNAs can act as promoters or tumor suppressors to induce resistance to chemo/radiotherapy in cancer through DNA damage repair and the inhibition of apoptosis. 46 The target of miRNAs can be a tumor suppressor gene.…”

“…An aberrant expression of one miRNA can affect hundreds of mRNAs and has a profound effect on cancer‐related signaling pathways. Animal models of various cancers and clinical studies showed that there is a causal relationship between miRNAs and cancer development, and as a result, miRNAs quickly entered the clinical stage as biomarkers and therapeutic targets 42–45 . miRNAs can act as promoters or tumor suppressors to induce resistance to chemo/radiotherapy in cancer through DNA damage repair and the inhibition of apoptosis 46 .…”